在标签之外使用气球可扩展的跨导管来治疗纯动脉吐
Mateusz Orzalkiewicz1, Marco Foroni1, Francesco Chietera1
1Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy.
The American journal of cardiology
|April 25, 2024
概括
使用超大气球可扩展 (BEV) 进行纯大动脉反 (AR) 的跨导管大动脉植入 (TAVI) 证明了良好的结果. 达到≥20%的超大小与可预测的程序成功和安全有关.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 过导管大动脉植入 (TAVI) 是一种已建立的对大动脉狭窄的治疗方法.
- 在标签之外使用气球膨胀 (BEV) 用于纯大动脉吐 (AR) 正在增加.
- 纯AR中BEV的最佳超大小化策略和安全数据仍然有限.
研究的目的:
- 评估BEV超大尺寸对纯AR患者TAVI结局的影响.
- 评估在不同大动脉环大小中实现≥20%超大小的可行性.
- 在这个患者队列中确定与超大BEV相关的安全性和技术成功率.
主要方法:
- 连续13名患者的回顾性分析,这些患者接受了使用Sapien BEV.进行纯AR的TAVI,并使用了SAPIEN BEV.
- 患者被分为小圆环 (SA; ≤618 mm2) 和大圆环 (LA; >618 mm2) 的两组.
- 术后计算机断层扫描被用来测量实际的超大小和过度扩张.
主要成果:
- 技术成功率为92.3%,在LA组中有一个膜栓塞.
- 平均超大尺寸为28.3%,在SA组 (31.2%) 显著高于LA组 (19.4%).
- 在100%的SA患者中,达到了≥20%的超大小,而在LA患者中达到了33.3%.
结论:
- 对于纯 AR 的超大 Sapien BEV 的 TAVI 显示出有希望的程序和短期结果.
- 可以预测达到≥20%的超大小是可行的,特别是在较小的大动脉环中.
- 需要进一步的研究来证实这种非标签方法的长期安全性和有效性.
相关概念视频
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


